TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02860260

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood samples

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cerebral MRI

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cerebral MRI
Study: NCT01511250

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2\*10\^4 PFU, 5\*10\^4 PFU, 1\*10\^5 PFU, and 3\*10\^5 PFU respectively, total virus per dose: 4.7\*10\^5 PFU.
Study: NCT02284893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with Saxagliptin
Description: administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with Dapagliflozin
Description: administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with Sitagliptin
Description: administered orally once daily
Study: NCT04440774

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHIK low dose
Description: A single dose of 5x10\^9 vp ChAdOx1 Chik

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHIK low dose
Description: A single dose of 5x10\^9 vp ChAdOx1 Chik

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHIK mid dose
Description: A single dose of 2.5x10\^10 vp ChAdOx1 Chik

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHIK mid dose
Description: A single dose of 2.5x10\^10 vp ChAdOx1 Chik

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHIK high dose
Description: A single dose of 5x10\^10 vp ChAdOx1 Chik

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHIK high dose
Description: A single dose of 5x10\^10 vp ChAdOx1 Chik

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZIKA low dose
Description: A single dose of 5x10\^9 vp ChAdOx1 Zika

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZIKA low dose
Description: A single dose of 5x10\^9 vp ChAdOx1 Zika

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZIKA mid dose
Description: A single dose of 2.5x10\^10 vp ChAdOx1 Zika

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZIKA mid dose
Description: A single dose of 2.5x10\^10 vp ChAdOx1 Zika

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZIKA high dose
Description: A single dose of 5x10\^10 vp ChAdOx1 Zika

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZIKA high dose
Description: A single dose of 5x10\^10 vp ChAdOx1 Zika

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: A single dose of isotonic saline solution (0.9%)
Study: NCT01061788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479, Everolimus, Panitumumab
Description: Dose Escalation Cohort #, Subjects, Everolimus, AMG 479~1. 3-6 subjects, Study drug administered per dose level~2. 3-6 subjects, Study drug administered per dose level~   Expanded Cohort Subjects, Everolimus, AMG 479 20 subjects, study drug administered per dose level~   Dose Escalation, Cohort #, Subjects, Everolimus, AMG 479, Panitumumab~3. 3-6 subjects, Study drug administered per dose level~4. 3-6 subjects, Study drug administered per dose level~Expanded Cohort Subjects, Everolimus, AMG 479, Panitumumab 20 subjects, Study drug administered per dose level~NSCLS Cohort Subjects, Everolimus, AMG 479, 20 subjects, Study drug administered per dose level
Study: NCT02686944

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intuvax (ilixadencel)
Description: Therapeutic vaccine: allogeneic, proinflammatory dendritic cells, suspension for intratumoral injection
Study: NCT06489509

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive End Expiratory Pressure 5 H2O
Description: Positive End Expiratory Pressure 5 H2O from CPAP apparatus

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive End Expiratory Pressure 5 H2O
Description: Positive End Expiratory Pressure 5 H2O from CPAP apparatus

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive End Expiratory Pressure 5 H2O
Description: Positive End Expiratory Pressure 5 H2O from CPAP apparatus

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive End Expiratory Pressure 10 H2O
Description: Positive End Expiratory Pressure 5 H2O from CPAP apparatus

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive End Expiratory Pressure 10 H2O
Description: Positive End Expiratory Pressure 5 H2O from CPAP apparatus
Study: NCT01511250

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2\*10\^4 PFU, 5\*10\^4 PFU, 1\*10\^5 PFU, and 3\*10\^5 PFU respectively, total virus per dose: 4.7\*10\^5 PFU.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2\*10\^4 PFU, 5\*10\^4 PFU, 1\*10\^5 PFU, and 3\*10\^5 PFU respectively, total virus per dose: 4.7\*10\^5 PFU.
Study: NCT06489509

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive End Expiratory Pressure 10 H2O
Description: Positive End Expiratory Pressure 5 H2O from CPAP apparatus
Study: NCT03935347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study: NCT00869661

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copegus
Description: 1000/1200mg po daily for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000/1200mg po daily for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 180 micrograms sc weekly for 24 or 48 weeks
Study: NCT01511250

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2\*10\^4 PFU, 5\*10\^4 PFU, 1\*10\^5 PFU, and 3\*10\^5 PFU respectively, total virus per dose: 4.7\*10\^5 PFU.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2\*10\^4 PFU, 5\*10\^4 PFU, 1\*10\^5 PFU, and 3\*10\^5 PFU respectively, total virus per dose: 4.7\*10\^5 PFU.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
Study: NCT04527614

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: qRT-PCR and serology
Description: qRT-PCR and serology

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: qRT-PCR and serology
Description: qRT-PCR and serology
Study: NCT00869661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 180 micrograms sc weekly for 24 or 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 180 micrograms sc weekly for 24 or 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 180 micrograms sc weekly for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: 180 micrograms sc weekly for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 180 micrograms sc weekly for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: 1000mg bid for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: 500mg bid for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: 1000mg bid for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: 1000mg bid for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: 1000mg bid for 12 weeks
Study: NCT00785681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermacyd PH_DETINBACK (Lactic Acid)
Study: NCT02518217

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss Apps
Description: Provision of commercially available smartphone applications for healthy eating, physical activity, and weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Apps
Description: Provision of commercially available smartphone applications for healthy eating, physical activity, and weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Apps
Description: Provision of commercially available smartphone applications for healthy eating, physical activity, and weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ShapeUp Empower
Description: Online intervention with training in behavioral strategies for healthy eating, physical activity, and weight loss. Includes periodic feedback on weight loss progress and engagement with the intervention platform.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ShapeUp Empower
Description: Online intervention with training in behavioral strategies for healthy eating, physical activity, and weight loss. Includes periodic feedback on weight loss progress and engagement with the intervention platform.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives for Engagement
Description: Financial incentives for completing tasks such as viewing instructional information and reporting self-monitored body weights via the study website.
Study: NCT05751876

Intervention type: DRUG
Intervention: Dienogest
Description: Dienogest 2mg was prescribed once per day orally
Study: NCT04044560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blinatumomab
Description: Continuous intravenous infusion
Study: NCT03818386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGuIX®
Description: 3 intravenous injection at 100mg/kg~* D0: AGuIX® injection followed by MRI (within 7 days before commencement of WBRT)~* Fr1: AGuIX® injection before the first radiation session~* Fr6: AGuIX® injection before the sixth radiation session

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Brain Radiation Therapy
Description: 30 Gy in 10 fractions of 3 Gy over 2-3 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole Brain Radiation Therapy
Description: 30 Gy in 10 fractions of 3 Gy over 2-3 weeks
Study: NCT04572204

Intervention type: OTHER
Intervention: Surgical
Description: Minimal: Such as PCN insertion Endosopic: Such as DJ insertion Surgical: Repair, Partial or total nephrectomy Angioembolization
Study: NCT01429831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: starting aripiprazole dose from 2-5mg/day, dose adjustment by every week, and maximum dose can up to 15mg/day. The duration is 6 weeks.
Study: NCT05181800

Intervention type: OTHER
Intervention: Degarelix Cohort
Description: Non-interventional
Study: NCT00224484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK208141
Description: 3 intramuscular doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix (investigational formulation)
Description: 3 intramuscular doses
Study: NCT03935347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Tumor Infiltrating Lymphocytes LN-145
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IV
Study: NCT02304185

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp140, 50 mcg
Description: Glycoprotein 140 (gp140) vaccine containing 50 microgram (mcg) total protein will be administered intramuscularly on Day 1 and Day 29.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp140, 50 mcg + Adjuvant
Description: The gp140 vaccine containing 50 mcg total protein mixed with 0.425 milligram (mg) aluminum phosphate adjuvant will be administered intramuscularly on Day 1 and Day 29.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp140, 250 mcg
Description: The gp140 vaccine containing 250 mcg total protein will be administered intramuscularly on Day 1 and Day 29.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp140, 250 mcg + Adjuvant
Description: The gp140 vaccine containing 250 mcg total protein mixed with 0.425 mg aluminum phosphate adjuvant will be administered intramuscularly on Day 1 and Day 29.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to gp 140 vaccine drug product will be administered intramuscularly on Day 1 and Day 29.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to gp 140 vaccine drug product will be administered intramuscularly on Day 1 and Day 29.
Study: NCT02290912

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education program
Description: The intervention is a health education program including: informational website, experiential classes, custom smart phone or smart table application, wearable activity monitor, and informal coaching by student researchers to provide moral support for lifestyle behavioral change goals. Participants are not placed on any specific behavioral regimen but instead are encouraged to adopt healthier lifestyle behaviors per the evidence-based health education program, and to attend the experiential classes cafeteria style (i.e. based on their individual preferences).
Study: NCT03725592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: Participant households receive a point of use arsenic removal device and a replacement filter. Households are also provided with an instruction manual on how to use the device.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Participant households receive a point of use arsenic removal device and a replacement filter. Households are also provided with an instruction manual on how to use the device.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Education
Description: Participant households receive up to five additional in-person visits and phone calls to provide support regarding the health implications of arsenic and the proper use and maintenance of the arsenic removal device.
Study: NCT02082977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2816126
Description: GSK2816126 will be supplied as a solution containing 15 milligram per milliliter (mg/mL) GSK2816126 in water for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2816126
Description: GSK2816126 will be supplied as a solution containing 15 milligram per milliliter (mg/mL) GSK2816126 in water for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2816126
Description: GSK2816126 will be supplied as a solution containing 15 milligram per milliliter (mg/mL) GSK2816126 in water for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2816126
Description: GSK2816126 will be supplied as a solution containing 15 milligram per milliliter (mg/mL) GSK2816126 in water for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2816126
Description: GSK2816126 will be supplied as a solution containing 15 milligram per milliliter (mg/mL) GSK2816126 in water for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2816126
Description: GSK2816126 will be supplied as a solution containing 15 milligram per milliliter (mg/mL) GSK2816126 in water for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2816126
Description: GSK2816126 will be supplied as a solution containing 15 milligram per milliliter (mg/mL) GSK2816126 in water for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2816126
Description: GSK2816126 will be supplied as a solution containing 15 milligram per milliliter (mg/mL) GSK2816126 in water for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2816126
Description: GSK2816126 will be supplied as a solution containing 15 milligram per milliliter (mg/mL) GSK2816126 in water for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2816126
Description: GSK2816126 will be supplied as a solution containing 15 milligram per milliliter (mg/mL) GSK2816126 in water for injection.
Study: NCT01215331

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulins most commonly used during pregnancy by our group are rapid acting insulins and long acting human insulins (long acting analogs are not authorized in pregnancy). An ultra-fast acting insulin will be started before a meal (1, 2 or 3 meals) at 4-6 IU (according to the weight) if the glycemic value 2 hours after this meal is ≥ 6.7 mmol/L in 50% of cases. It will be increased by 2 units every 2 days until obtaining the aimed objectives. Long acting insulin will be started at 4-6 units at bedtime if the glycemic value before breakfast is ≥ 5.3 mmol/L in 50% of cases, and it will be increased by 2 units every 2 days until reaching the objective. A combination of both insulins could be necessary (maximum of 4 injections per day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin, glyburide and insulin
Description: Metformin (tablets of 500 mg) will be started at 250 mg/day x 1 day, and increased thereafter by 250 mg per day every 3 days until obtaining an adequate glycemic control. If metformin does not prove its effect at a dose of 750 mg, or if the side effects (mainly gastric) command to slow down or not to increase the posology, glyburide will be added.~Glyburide (tablets of 5 mg) will be started at a dose of 2.5 mg and will be increased by 2.5 mg every 3 days until obtaining an adequate glycemic control. The maximal dose in the study will bw 10 mg. It corresponds to the half of the maximal dose recommended in Canada.~Treatment failure is defined as glycemia above the Canadian Diabetes Association therapeutic objectives in spite of maximal doses or whether the doses can not be increased because of side effects. Insulin will be added to oral hypoglycemic agents.
Study: NCT00224484

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 intramuscular doses
Study: NCT03497819

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CARTmeso CART19
Description: Autologous chimeric antigen receptor T cells with murine scFv, 41BB co-stimulatory domain and CD3ζ signaling domain targeting mesothelin or CD19
Study: NCT01839695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valiant Mona LSA Stent Graft System
Description: All subjects will be implanted with this device
Study: NCT03176524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone® glucagon formulation 1
Description: Injection of BioChaperone® glucagon formulation 1 at Day 1: 50 µg and at Day 2: 1 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone® glucagon formulation 2
Description: Injection of BioChaperone® glucagon formulation 2 at Day 1: 50 µg and at Day 2: 1 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GlucaGen® HypoKit®
Description: Injection of GlucaGen® HypoKit® at Day 1: 50 µg and at Day 2: 1 mg
Study: NCT01085448

Intervention type: OTHER
Group type: OTHER
Intervention: Core Stabilization
Description: The 8-week program emphasizes use of specific local stabilizing muscles (transverse abdominis\[TrA\], lumbar multifidus\[LM\]) to restore active control to the trunk. Emphasis is on training isometric co-contractions and a progression (3 stages) based upon a motor learning paradigm.~Stage 1: neutral position of the spine and activation of the TrA and LM. Performance feedback is emphasized and monitored through observation and palpation.~Stage 2: maintenance the co-contraction while performing movements of the trunk and the upper and lower extremities. Trunk conditioning is also emphasized. Feedback is gradually reduced.~Stage 3: maintenance of the co-contraction while performing exercises on an unstable surface or during perturbation of the activity. Random practice patterns are used to enhance motor learning.
Study: NCT04601402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEN-001
Description: The capsules taken by mouth once a daily. Each capsule will contain ≥ 1x10\^11 colony-forming units (CFU)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: 800 mg given by intravenous (IV) infusion once every 2 weeks
Study: NCT02514525

Intervention type: DEVICE
Group type: OTHER
Intervention: CryoBalloon Ablation System
Description: CryoBalloon Ablation System, a balloon-based cryotherapy device, provides controlled ablation for the treatment of BE. Deployed through the working channel of an endoscope, the Balloon is simultaneously inflated and cooled with an inert cryogen (nitrous oxide) delivered from the handle that ablates the BE cells upon contact with the esophagus.
Study: NCT02171065

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ABSORB BVS
Study: NCT01435278

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glucosanol
Description: 2 tablets taken 3 times a day.